Expert Review of Anticancer Therapy最新文献

The effect of dose reduction of CDK4/6 inhibitors on survival in postmenopausal HR+ HER2-negative metastatic breast cancer. CDK4/6抑制剂剂量减少对绝经后HR+ her2阴性转移性乳腺癌患者生存的影响

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-04-08 DOI: 10.1080/14737140.2025.2490289

Furkan Ceylan, Safa Can Efil, Didem Sener, Ates Kutay Tenekeci, Burak Bilgin, Şebnem Yücel, Eren Göktuğ Ceylan, Mutlu Hızal, Mehmet Ali Nahit Şendur, Muhammed Bülent Akıncı, Öznur Bal, Bülent Yalçın

{"title":"The effect of dose reduction of CDK4/6 inhibitors on survival in postmenopausal HR+ HER2-negative metastatic breast cancer.","authors":"Furkan Ceylan, Safa Can Efil, Didem Sener, Ates Kutay Tenekeci, Burak Bilgin, Şebnem Yücel, Eren Göktuğ Ceylan, Mutlu Hızal, Mehmet Ali Nahit Şendur, Muhammed Bülent Akıncı, Öznur Bal, Bülent Yalçın","doi":"10.1080/14737140.2025.2490289","DOIUrl":"https://doi.org/10.1080/14737140.2025.2490289","url":null,"abstract":"Background: This study aimed to evaluate the effect of dose reduction of CDK4/6 inhibitors on survival outcomes in postmenopausal patients with HR+ HER2-negative metastatic breast cancer (mBC).Methods: A retrospective cohort study was conducted involving 164 postmenopausal patients with HR+ HER2-negative mBC who received CDK4/6 inhibitors between 2021 and 2024. Clinical parameters were systematically analyzed. Progression-free survival (PFS) and overall survival (OS) were evaluated based on dose reduction status. Survival outcomes were estimated using the Kaplan-Meier method, and independent prognostic factors were identified through multivariate Cox regression analysis.Results: The median age was 61 years, with a median follow-up of 23.5 months. The median PFS was 23.3 months, while median OS was not reached. Dose reduction occurred in 45 patients (27%), who exhibited significantly worse survival (PFS HR: 1.67, 95% CI: 1.02-2.72, p = 0.042; OS HR: 2.54, 95% CI: 1.34-4.83, p = 0.004). Dose reduction and liver metastases were independent risk factors for shorter PFS and OS, while treatment in later lines was associated with shorter PFS.Conclusion: Dose reductions in CDK4/6 inhibitors were associated with worse survival outcomes in postmenopausal HR+ HER2- mBC patients. Future biomarker-driven studies are needed to guide personalized dose adjustments and optimize treatment efficacy.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Contemporary management of diffuse large B-cell lymphoma in Japan. 日本弥漫大b细胞淋巴瘤的当代治疗。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-04-08 DOI: 10.1080/14737140.2025.2490283

Katsuhiro Miura, Hiromichi Takahashi, Haruna Nishimaki-Watanabe, Takashi Hamada, Akihiro Uchiike, Daisuke Tsutsumi, Shimon Ohtake, Kazuhide Iizuka, Takashi Koike, Kazuya Kurihara, Toshihide Endo, Tatsuya Hayama, Masaru Nakagawa, Noriyoshi Iriyama, Yoshihiro Hatta, Hideki Nakamura

{"title":"Contemporary management of diffuse large B-cell lymphoma in Japan.","authors":"Katsuhiro Miura, Hiromichi Takahashi, Haruna Nishimaki-Watanabe, Takashi Hamada, Akihiro Uchiike, Daisuke Tsutsumi, Shimon Ohtake, Kazuhide Iizuka, Takashi Koike, Kazuya Kurihara, Toshihide Endo, Tatsuya Hayama, Masaru Nakagawa, Noriyoshi Iriyama, Yoshihiro Hatta, Hideki Nakamura","doi":"10.1080/14737140.2025.2490283","DOIUrl":"10.1080/14737140.2025.2490283","url":null,"abstract":"Introduction: Despite the heterogeneity of diffuse large B-cell lymphoma (DLBCL), treatment approaches are remarkably well-standardized. However, its management differs according to socio-economic and medical environments.Areas covered: This review analyzed the latest trends in DLBCL diagnosis and treatment in Japan, where the national universal healthcare insurance covers the cost of novel modalities, such as polatuzumab vedotin, chimeric antigen receptor T cells (CAR-T), or bispecific antibodies (BsAb). Given the particularly high incidence, we spotlighted DLBCL in older adults. CD5-positive (CD5+) DLBCL and intravascular large B-cell lymphoma (IVLBCL) were also discussed based on the leading trials conducted in Japan.Expert opinion: The accurate pathologic diagnosis of DLBCL made by experts or via consultation networks is essential, and an emerging genomic assay will contribute to future precision approaches. Although polatuzumab vedotin is frequently used in the first-line treatment of patients with advanced disease, its application should be carefully analyzed. As the number of older patients increases, the importance of pre-treatment geriatric assessment becomes apparent. CD5+ DLBCL and IVLBCL adopt distinct strategies with high-dose methotrexate, but their benefits warrant further evaluation. CAR-T and BsAb are increasingly used to treat patients with relapsed and refractory diseases. A cost-effective evaluation of these novel approaches is required.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-9"},"PeriodicalIF":2.9,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143795047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Alternative regimen for chemotherapy-intolerant lymphoma including practical aspects in Japan. 化疗不耐受淋巴瘤的替代方案，包括日本的实践方面。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-04-06 DOI: 10.1080/14737140.2025.2488317

Akihiro Ohmoto, Shigeo Fuji

{"title":"Alternative regimen for chemotherapy-intolerant lymphoma including practical aspects in Japan.","authors":"Akihiro Ohmoto, Shigeo Fuji","doi":"10.1080/14737140.2025.2488317","DOIUrl":"10.1080/14737140.2025.2488317","url":null,"abstract":"Introduction: With the increasing number of elderly patients with lymphoma and the emergence of novel agents, clinical investigations for patients considered intolerant to conventional cytotoxic chemotherapy are receiving more focus than before.Areas covered: This review aims to provide an overview of systemic treatment for patients with lymphoma who are intolerant to conventional chemotherapy, including practical aspects in Japan.Expert opinion: Traditional approaches include dose reduction (e.g. mini-CHOP) or non-anthracycline regimens (e.g. CVP or bendamustine-based regimens) to reduce the risk of cardiotoxicity. A recent trend is the combination of molecular-targeted agents, such as lenalidomide plus rituximab in B-cell lymphoma. However, maintaining durable responses remains a major challenge. In the future, clinical trials in elderly or frail patients are expected to investigate novel agents such as antibody-drug conjugates or bispecific T-cell engagers. In addition, comprehensive geriatric assessment for tailored therapeutic intervention or dose optimization strategies based on individual genomic data is expected in the context of prospective studies.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-11"},"PeriodicalIF":2.9,"publicationDate":"2025-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effectiveness and safety of therapies for hepatocellular carcinoma with tumor thrombus in the hepatic vein, inferior vena cave and/or right atrium: a systematic review and single-arm meta-analysis. 肝静脉、下腔静脉和/或右心房肿瘤血栓肝细胞癌治疗的有效性和安全性：一项系统综述和单臂荟萃分析

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-04-06 DOI: 10.1080/14737140.2025.2489651

Qing-Bo Wang, Jin Li, Zi-Jun Zhang, Yu-Kai Li, Yu-Bo Liang, Xing-Ming Chen, Wan-Ling Luo, Yawhan Lakang, Zi-Sheng Yang, Guan-Yi Liu, Yu Liu, Shuang-Xi Li, Yang Ke

{"title":"The effectiveness and safety of therapies for hepatocellular carcinoma with tumor thrombus in the hepatic vein, inferior vena cave and/or right atrium: a systematic review and single-arm meta-analysis.","authors":"Qing-Bo Wang, Jin Li, Zi-Jun Zhang, Yu-Kai Li, Yu-Bo Liang, Xing-Ming Chen, Wan-Ling Luo, Yawhan Lakang, Zi-Sheng Yang, Guan-Yi Liu, Yu Liu, Shuang-Xi Li, Yang Ke","doi":"10.1080/14737140.2025.2489651","DOIUrl":"10.1080/14737140.2025.2489651","url":null,"abstract":"Background: This review evaluates the efficacy and safety of therapies for hepatocellular carcinoma (HCC) with hepatic vein tumor thrombus (HVTT), inferior vena cava tumor thrombus (IVCTT), and/or right atrium tumor thrombus (RATT).Research design and methods: A systematic review of PubMed, EMBASE, Cochrane Library, and Wanfang databases up to 22 August 2024, was conducted, focusing on overall survival (OS), progression -free survival (PFS), and adverse reactions.Results: Seven studies involving 453 patients were analyzed. Treatment strategies included surgery alone, local ± systemic therapy, and surgery with adjuvant therapy. The pooled 1-, 3-, and 5-year OS rates for all patients were 63.3%, 21.6% , and 8.3%, respectively. Surgery with adjuvant therapy achieved the highest 1-year OS, while local ± systemic therapy led to the best 5-year OS. The pooled 1-, 3-, and 5-year PFS rates for all patients were 56.8%, 9.4%, and 1.6%, respectively. Surgery alone commonly caused ascites and pleural effusion; the local ± systemic therapy commonly caused hepatic dysfunction and platelet abnormalities; and surgery with adjuvant therapy commonly caused peritoneal abscess.Conclusion: Local ± systemic therapy provided the best long-term OS and manageable complications among the therapeutic strategies for HCC with HVTT, IVCTT, and/or RATT.Registration: PROSPERO, (CRD42024573152).","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-10"},"PeriodicalIF":2.9,"publicationDate":"2025-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143778953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prostate cancer in central and Eastern Europe: a comprehensive regional analysis of burden, trends, and future projections based on the global burden of disease study (1990-2021). 中欧和东欧的前列腺癌：基于全球疾病负担研究（1990-2021年）的负担、趋势和未来预测的综合区域分析

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-04-06 DOI: 10.1080/14737140.2025.2483853

Prakasini Satapathy, Shilpa Gaidhane, Gaurav Sanghvi, Subbulakshmi Ganesan, Swati Mishra, Krishnakumar Samikan, Ashutosh Jena, Mahendra Singh, Sanjit Sah, Shubham Kumar, Khang Wen Goh, Muhammed Shabil

{"title":"Prostate cancer in central and Eastern Europe: a comprehensive regional analysis of burden, trends, and future projections based on the global burden of disease study (1990-2021).","authors":"Prakasini Satapathy, Shilpa Gaidhane, Gaurav Sanghvi, Subbulakshmi Ganesan, Swati Mishra, Krishnakumar Samikan, Ashutosh Jena, Mahendra Singh, Sanjit Sah, Shubham Kumar, Khang Wen Goh, Muhammed Shabil","doi":"10.1080/14737140.2025.2483853","DOIUrl":"10.1080/14737140.2025.2483853","url":null,"abstract":"Objectives: This study aims to assess the burden of prostate cancer (PCa) in Central and Eastern Europe (CEE) by analyzing historical trends, evaluating the current burden, and forecasting future trends.Methods: This study uses data from the Global Burden of Disease (GBD) study spanning 1990-2021 to analyze PCa trends in CEE. We assessed age-standardized rates (ASRs) of PCa to identify trend changes through joinpoint regression analysis, explored regional disparities using QGIS software, and made projections for 2031 using the ARIMA model.Results: Eastern Europe experienced greater changes across health metrics compared to Central Europe, with higher average annual percentage change values for incidence, prevalence, mortality, and DALYs rates. In 2021, Lithuania and Estonia recorded the highest PCa prevalence rates, while Estonia had the highest total percentage change (240.3). Estonia and Latvia also had the highest mortality rates (34.1 and 33.6 per 100,000, respectively). CEE's prevalence rates are projected to remain stable.Conclusion: The findings highlight significant regional disparities in the burden of prostate cancer in CEE. Efforts to address these disparities should focus on enhancing diagnostic programs and treatment access, particularly in Eastern Europe, to reduce the ongoing burden of PCa in the region.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-7"},"PeriodicalIF":2.9,"publicationDate":"2025-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143700102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in liquid biopsy and virtual biopsy for care of patients with glioma: a narrative review. 液体活检和虚拟活检在胶质瘤患者护理中的进展：叙述性回顾。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-04-05 DOI: 10.1080/14737140.2025.2489629

Muhammad Awais, Abdul Rehman, Syed Sarmad Bukhari

{"title":"Advances in liquid biopsy and virtual biopsy for care of patients with glioma: a narrative review.","authors":"Muhammad Awais, Abdul Rehman, Syed Sarmad Bukhari","doi":"10.1080/14737140.2025.2489629","DOIUrl":"10.1080/14737140.2025.2489629","url":null,"abstract":"Introduction: The World Health Organization's 2021 classification of central nervous system neoplasms incorporated molecular and genetic features for classifying gliomas. Classification of gliomas located in deep-seated structures became a clinical conundrum given the absence of crucial pathological and molecular data. Advances in noninvasive imaging modalities offered virtual biopsy as a novel solution to this problem by identifying surrogate radiomic signatures. Liquid biopsies of blood or cerebrospinal fluid provided another enormous opportunity for identifying genomic, metabolomic and proteomic signatures.Areas covered: We summarize and appraise the current state of evidence with regards to virtual biopsy and liquid biopsy in the care of patients with gliomas. PubMed, Embase and Google Scholar were searched on 7/30/2024 for relevant articles published after the year 2013 in the English language.Expert opinion: A large body of preclinical and preliminary clinical evidence suggests that virtual biopsy is possible with the combined use of multiple novel imaging modalities in conjunction with machine learning and radiomics. Likewise, liquid biopsy in conjunction with focused ultrasound may be a valuable tool to obtain proteomic and genomic data regarding glioma in a minimally invasive manner. These modalities will likely become an integral part of care for patients with glioma in the future.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-22"},"PeriodicalIF":2.9,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143778939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current and emerging treatment perspectives for adults with Waldenström macroglobulinemia. 成人Waldenström巨球蛋白血症的当前和新出现的治疗观点。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-04-03 DOI: 10.1080/14737140.2025.2488312

Alberto Guijosa, Shayna Sarosiek, Jorge J Castillo

{"title":"Current and emerging treatment perspectives for adults with Waldenström macroglobulinemia.","authors":"Alberto Guijosa, Shayna Sarosiek, Jorge J Castillo","doi":"10.1080/14737140.2025.2488312","DOIUrl":"https://doi.org/10.1080/14737140.2025.2488312","url":null,"abstract":"Introduction: Waldenström Macroglobulinemia (WM) is distinguished from other indolent lymphomas by its unique molecular landscape and clinical behavior. With the emergence of new therapeutic options and improved survival rates, it has become increasingly important to balance the goal of prolonging survival with minimizing treatment-related toxicities.Areas covered: This review focuses on the current therapeutic strategies for WM, emphasizing the clinical effectiveness of various agents and treatment groups and their associated toxicity profiles. Additionally, we discuss emerging therapies and combinations, which have shown encouraging preliminary results.Expert opinion: WM remains an incurable disease, yet its indolent nature and the growing array of therapeutic options have significantly improved outcomes in first- and subsequent-line settings. Chemoimmunotherapy and BTK inhibitors have demonstrated high efficacy and durable responses, with the latter offering a stem-cell-sparing approach. However, unlike in CLL or multiple myeloma, evidence supporting the superiority of targeted agents over chemoimmunotherapy is not available. Consequently, treatment decisions depend on patient characteristics and shared decision-making to carefully balance risks, select appropriate regimens, and encourage clinical trial participation to advance in understanding this rare disease.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-13"},"PeriodicalIF":2.9,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Melanoma neoadjuvant treatment: review and update of recent trials. 黑色素瘤新辅助治疗：近期试验的回顾和更新。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-04-01 Epub Date: 2025-03-14 DOI: 10.1080/14737140.2025.2474182

Marco Ferrari, Bianca Arianna Facchini, Paolo Antonio Ascierto, Francesca Sparano

{"title":"Melanoma neoadjuvant treatment: review and update of recent trials.","authors":"Marco Ferrari, Bianca Arianna Facchini, Paolo Antonio Ascierto, Francesca Sparano","doi":"10.1080/14737140.2025.2474182","DOIUrl":"10.1080/14737140.2025.2474182","url":null,"abstract":"Introduction: Neoadjuvant immunotherapy is emerging as an effective approach for resectable stage III/IV melanoma, showing improvements in disease response and survival outcomes.Areas covered: This review summarizes findings from neoadjuvant treatment trials in melanoma patients. Using the PubMed search engine and including the keywords 'neoadjuvant,' 'immunotherapy,' and 'melanoma,' we selected 18 trials that showed efficacy in patients with melanoma, mainly testing checkpoint inhibitors alone or in combination. Across all trials examined, treatments showed objective disease responses, which frequently translated into improved disease-free survival.Expert opinion: Additional phase III studies comparing neoadjuvant and adjuvant therapies are needed to establish the optimal standard of care. The variety of regimens and dosing schedules investigated highlights the need for further research to determine the most appropriate treatments in this clinical setting. Advances in the study of biomarkers that can identify specific subgroups of patients will guide future research in this field.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"383-392"},"PeriodicalIF":2.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143566380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An evaluation of nivolumab plus gemcitabine and cisplatin in the treatment of advanced urothelial carcinoma. 纳武单抗联合吉西他滨和顺铂治疗晚期尿路上皮癌的评价。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-04-01 Epub Date: 2025-03-04 DOI: 10.1080/14737140.2025.2473645

Eric J Miller, Matthew D Galsky

{"title":"An evaluation of nivolumab plus gemcitabine and cisplatin in the treatment of advanced urothelial carcinoma.","authors":"Eric J Miller, Matthew D Galsky","doi":"10.1080/14737140.2025.2473645","DOIUrl":"10.1080/14737140.2025.2473645","url":null,"abstract":"Introduction: For decades, first-line treatment for advanced/metastatic urothelial cancer has been platinum-based chemotherapy. However, many patients do not respond to platinum-based chemotherapy alone, and the vast majority do not have durable responses. While immune checkpoint blockade has demonstrated benefit in this setting, initial trials of concurrent chemotherapy and immune checkpoint blockade did not demonstrate improvements in overall survival.Areas covered: The recent CheckMate 901 trial compared gemcitabine, cisplatin, plus nivolumab to gemcitabine and cisplatin alone for first-line treatment of advanced/metastatic urothelial cancer. This was the first trial to demonstrate significant benefit in the combined chemotherapy and immune checkpoint blockade arm in advanced/metastatic urothelial cancer, most significantly showing an improvement in the primary outcomes of progression-free survival and overall survival, and the exploratory outcomes of objective response rate, complete response rate, and duration of complete response.Expert opinion: The combination of gemcitabine, cisplatin, plus nivolumab represents a new first-line treatment option for metastatic urothelial cancer. This article details the clinical benefit observed and how this establishes proof-of-concept for prior hypotheses related to the importance of the specific chemotherapy regimen combined with immune checkpoint blockade, revolving around immunomodulatory mechanisms of action of cisplatin, and synergy of these mechanisms with immunotherapy.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"319-326"},"PeriodicalIF":2.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143522832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances and future directions in radiopharmaceutical delivery for cancer treatment. 放射性药物在癌症治疗中的应用进展及未来发展方向。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-04-01 Epub Date: 2025-03-03 DOI: 10.1080/14737140.2025.2472859

Sikander Ailawadhi, Deanna Pafundi, Jennifer Peterson

{"title":"Advances and future directions in radiopharmaceutical delivery for cancer treatment.","authors":"Sikander Ailawadhi, Deanna Pafundi, Jennifer Peterson","doi":"10.1080/14737140.2025.2472859","DOIUrl":"10.1080/14737140.2025.2472859","url":null,"abstract":"Introduction: Targeted radiopharmaceutical therapies (RPTs) have emerged as a promising approach for the precise treatment of various cancers. Delivering ionizing radiation directly to cancer cells while sparing surrounding healthy tissue, radiopharmaceuticals offer enhanced efficacy and reduced toxicity compared to conventional external beam radiation therapy (i.e. photons and electrons).Areas covered: In the current era of personalized cancer care, the appropriate choice of RPTs for a clinical condition and the specific patient's care needs to be better understood. Several available RPT agents with their respective clinical applicability along with rapidly ongoing research in this field have now given RPTs the ability to lend themselves to a personalized medicine focus. This review provides an overview of recent advancements in RPT, including nuclide selection and development, molecular targeting strategies, radiopharmaceutical development, and clinical applications.Expert opinion: We discuss the underlying principles, challenges, and opportunities for future development. Furthermore, we explore emerging technologies and future directions in the field, highlighting the potential impact on personalized cancer care.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"351-361"},"PeriodicalIF":2.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143522830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0